Animal models of anxiety and anxiolytic drug action.

作者: Dallas Treit , Elif Engin , Kris McEown

DOI: 10.1007/7854_2009_17

关键词:

摘要: Animal models of anxiety attempt to represent some aspect the etiology, symptomatology, or treatment human disorders, in order facilitate their scientific study. Within this context, animal anxiolytic drug action can be viewed as relevant pharmacological control anxiety. A major purpose these is identify novel compounds and study mechanisms whereby produce effects. After a critical analysis “face,” “construct,” “predictive” validity, biological context which are evaluated specified. We then review terms general profiles, with particular attention sensitivity 5-HT1A agonists antidepressant compounds. Although there important exceptions, most sensitive one perhaps two classes compounds, limiting generality somewhat, but allowing depth individual (e.g., GABAA agonism). end discussion possible sources variability between response drugs.

参考文章(356)
S. Mora, G. Díaz-Véliz, R. Millán, H. Lungenstrass, S. Quirós, T. Coto-Morales, M.C. Hellión-Ibarrola, Anxiolytic and antidepressant-like effects of the hydroalcoholic extract from Aloysia polystachya in rats Pharmacology, Biochemistry and Behavior. ,vol. 82, pp. 373- 378 ,(2005) , 10.1016/J.PBB.2005.09.007
Victoria B. Risbrough, Mark A. Geyer, Anxiogenic treatments do not increase fear-potentiated startle in mice. Biological Psychiatry. ,vol. 57, pp. 33- 43 ,(2005) , 10.1016/J.BIOPSYCH.2004.10.006
Jeanne Stemmelin, Caroline Cohen, Jean-Paul Terranova, Matilde Lopez-Grancha, Philippe Pichat, Olivier Bergis, Michel Decobert, Vincent Santucci, Dominique Françon, Richard Alonso, Stephen M Stahl, Peter Keane, Patrick Avenet, Bernard Scatton, Gérard le Fur, Guy Griebel, Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology. ,vol. 33, pp. 574- 587 ,(2008) , 10.1038/SJ.NPP.1301424
Gerd D Bartoszyk, Rainer Hegenbart, Herbert Ziegler, EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties European Journal of Pharmacology. ,vol. 322, pp. 147- 153 ,(1997) , 10.1016/S0014-2999(96)00999-5
Peter Vis, Oscar Della Pasqua, Menno Kruk, Delphine Martin, Elisabeth Mocaër, Meindert Danhof, Roeline Jochemsen, Population pharmacokinetic–pharmacodynamic modelling of S 15535, a 5-HT1A receptor agonist, using a behavioural model in rats European Journal of Pharmacology. ,vol. 414, pp. 233- 243 ,(2001) , 10.1016/S0014-2999(01)00801-9
Jean-Georges Rohmer, Georges Di Scala, Guy Sandner, Behavioral analysis of the effects of benzodiazepine receptor ligands in the conditioned burying paradigm. Behavioural Brain Research. ,vol. 38, pp. 45- 54 ,(1990) , 10.1016/0166-4328(90)90023-8
R. M. McKernan, T. W. Rosahl, D. S. Reynolds, C. Sur, K. A. Wafford, J. R. Atack, S. Farrar, J. Myers, G. Cook, P. Ferris, L. Garrett, L. Bristow, G. Marshall, A. Macaulay, N. Brown, O. Howell, K. W. Moore, R. W. Carling, L. J. Street, J. L. Castro, C. I. Ragan, G. R. Dawson, P. J. Whiting, Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nature Neuroscience. ,vol. 3, pp. 587- 592 ,(2000) , 10.1038/75761
B Olivier, H.E Molewijk, J.A.M van der Heyden, R van Oorschot, E Ronken, J Mos, K.A Miczek, Ultrasonic vocalizations in rat pups: effects of serotonergic ligands Neuroscience & Biobehavioral Reviews. ,vol. 23, pp. 215- 227 ,(1998) , 10.1016/S0149-7634(98)00022-0